Predictive testing for Huntington disease: interpretation and significance of intermediate alleles - PubMed (original) (raw)
Review
Predictive testing for Huntington disease: interpretation and significance of intermediate alleles
A Semaka et al. Clin Genet. 2006 Oct.
Erratum in
- Clin Genet. 2007 Jan;71(1):99
Abstract
Direct mutation analysis for Huntington disease (HD) became possible in 1993 with the identification of an expanded CAG trinucleotide repeat as the mutation underlying the disease. Expansion of CAG length beyond 35 repeats may be associated with the clinical presentation of HD. HD has never been seen in a person with a CAG size of <36 repeats. Intermediate alleles are defined as being below the affected CAG range but have the potential to expand to >35 CAG repeats within one generation. Thus, children of intermediate allele carriers have a low risk of developing HD. Currently, the intermediate allele range for HD is between 27 and 35 CAG repeats. In this study, we review the current knowledge on intermediate alleles for HD including the CAG repeat range, the intermediate allele frequency, and the clinical implications of an intermediate allele predictive test result. The factors influencing CAG repeat expansion, including the CAG size of the intermediate allele, the sex and age of the transmitting parent, the family history, and the HD gene sequence and haplotype, will also be reviewed.
Similar articles
- Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects.
Goldberg YP, Kremer B, Andrew SE, Theilmann J, Graham RK, Squitieri F, Telenius H, Adam S, Sajoo A, Starr E, et al. Goldberg YP, et al. Nat Genet. 1993 Oct;5(2):174-9. doi: 10.1038/ng1093-174. Nat Genet. 1993. PMID: 8252043 - Exploring the correlates of intermediate CAG repeats in Huntington disease.
Ha AD, Jankovic J. Ha AD, et al. Postgrad Med. 2011 Sep;123(5):116-21. doi: 10.3810/pgm.2011.09.2466. Postgrad Med. 2011. PMID: 21904093 Review. - CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease.
Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. Semaka A, et al. J Med Genet. 2013 Oct;50(10):696-703. doi: 10.1136/jmedgenet-2013-101796. Epub 2013 Jul 29. J Med Genet. 2013. PMID: 23896435 - Inherited CAG.CTG allele length is a major modifier of somatic mutation length variability in Huntington disease.
Veitch NJ, Ennis M, McAbney JP; US-Venezuela Collaborative Research Project; Shelbourne PF, Monckton DG. Veitch NJ, et al. DNA Repair (Amst). 2007 Jun 1;6(6):789-96. doi: 10.1016/j.dnarep.2007.01.002. Epub 2007 Feb 12. DNA Repair (Amst). 2007. PMID: 17293170 - Advances in Huntington's disease diagnostics: development of a standard reference material.
Levin BC, Richie KL, Jakupciak JP. Levin BC, et al. Expert Rev Mol Diagn. 2006 Jul;6(4):587-96. doi: 10.1586/14737159.6.4.587. Expert Rev Mol Diagn. 2006. PMID: 16824032 Review.
Cited by
- Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.
Krause A, Mitchell C, Essop F, Tager S, Temlett J, Stevanin G, Ross C, Rudnicki D, Margolis R. Krause A, et al. Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):573-85. doi: 10.1002/ajmg.b.32332. Epub 2015 Jun 16. Am J Med Genet B Neuropsychiatr Genet. 2015. PMID: 26079385 Free PMC article. - Prospects for neuroprotective therapies in prodromal Huntington's disease.
Chandra A, Johri A, Beal MF. Chandra A, et al. Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Mov Disord. 2014. PMID: 24573776 Free PMC article. Review. - Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal.
Bhat A, Dalvi H, Jain H, Rangaraj N, Singh SB, Srivastava S. Bhat A, et al. Curr Res Pharmacol Drug Discov. 2020 Dec 31;2:100012. doi: 10.1016/j.crphar.2020.100012. eCollection 2021. Curr Res Pharmacol Drug Discov. 2020. PMID: 34909647 Free PMC article. Review. - Genome-wide sequencing as a first-tier screening test for short tandem repeat expansions.
Rajan-Babu IS, Peng JJ, Chiu R; IMAGINE Study; CAUSES Study; Li C, Mohajeri A, Dolzhenko E, Eberle MA, Birol I, Friedman JM. Rajan-Babu IS, et al. Genome Med. 2021 Aug 9;13(1):126. doi: 10.1186/s13073-021-00932-9. Genome Med. 2021. PMID: 34372915 Free PMC article. - Huntington disease reduced penetrance alleles occur at high frequency in the general population.
Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Kay C, et al. Neurology. 2016 Jul 19;87(3):282-8. doi: 10.1212/WNL.0000000000002858. Epub 2016 Jun 22. Neurology. 2016. PMID: 27335115 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical